Maternal Embryo Interaction in Recurrent Miscarriages
MEER
The Maternal-embryo Interaction and Its Role in the Etiology of Recurrent Miscarriages
3 other identifiers
observational
58
1 country
1
Brief Summary
Background of the study: The etiology of recurrent miscarriage (RM, defined as three or more consecutive miscarriages without any proven maternal or fetal cause), remains undiagnosed in more than 50% of cases. In these cases it is generally considered that a disturbance in the normal mother-embryo interactions is a causal factor. This disturbance may be based on a dysregulation of embryo invasiveness and/or decidual acceptance (e.g. altered decidualization; endometrial changes in preparation for the acceptance of a putative pregnancy). Moreover, dysfunctional maternal immune regulatory natural killer (NK) cells, implicated in tolerance induction and trophoblast invasion,may also underlie the occurrence of RM. The Selection Failure hypothesis for RM suggests that super-receptive endometrium (possibly due to increased embryo invasiveness and/or decidual acceptance and/or dysregulated immune cell function) may allow 'poor quality' embryos to implant and present as a clinical pregnancy before miscarrying. Fundamental knowledge on mechanisms of embryo implantation, decidual function and maternal immune reactivity in successful pregnancies has accumulated over the past 5 years. This study aims to investigate whether dysregulation of (one of) these mechanisms may underlie RM. Objective of the study: To test The Selection Failure hypothesis by assessing A) the degree of embryo invasiveness and decidual acceptance (the quality of decidualization, endometrium-embryo communication and endometrial stromal cell (ESC) migration) and B) the angiogenic capacity of decidual NK (dNK) cells, in order to elucidate the pattern of the mother-embryo equilibrium in women with RM.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2010
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 1, 2010
CompletedStudy Start
First participant enrolled
June 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2012
CompletedFirst Posted
Study publicly available on registry
May 17, 2017
CompletedMay 17, 2017
May 1, 2017
1.1 years
April 1, 2010
May 15, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Embryo survival on decidualized ESCs of RM patients or fertile controls (Embryo survival as an indirect measure of embryo invasiveness)
Embryo survival as an indirect measure of embryo invasiveness
2 years
Study Arms (2)
Recurrent miscarriage group
Women with unexplained recurrent miscarriages (three or more first trimester miscarriages).
Control group
Proven fertile women (at least 1 successful pregnancy and no more than 1 miscarriage).
Eligibility Criteria
Recurrent miscarriage group: primary care clinic Control group: primary care clinic/community sample
You may qualify if:
- Women with unexplained recurrent miscarriages (three or more first trimester miscarriages).
- Proven fertile women (at least 1 successful pregnancy and no more than 1 miscarriage).
- Age 18 - 40 years.
- Willing and able to give informed consent.
You may not qualify if:
- Any identifiable causes of recurrent miscarriages; antiphospholipid syndrome (lupus anticoagulant and/or anticardiolipin antibodies \[IgG or IgM\]), other recognised thrombophilic conditions (testing according to usual clinic practice), intrauterine abnormalities (as assessed by ultrasound, hysterosonography, hysterosalpingogram or hysteroscopy), submucous fibroids and tests initiated only if clinically indicated such as tests for diabetes, thyroid disease and SLE
- Undergoing treatment (hormonal)
- Women using oral contraception or having an intra uterine device.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UMC Utrechtlead
Study Sites (1)
University Medical Center
Utrecht, Netherlands
Biospecimen
endometrial biopsies and peripheral blood samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Cobi J Heijnen, Prof. dr.
UMC Utrecht
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 1, 2010
First Posted
May 17, 2017
Study Start
June 1, 2010
Primary Completion
July 1, 2011
Study Completion
July 1, 2012
Last Updated
May 17, 2017
Record last verified: 2017-05